March 15, 2016
Wellesley, Mass., March 15, 2016 – The central nervous system (CNS) biomarkers market presents the largest of all opportunities in representative disease subsegments. BCC Research reveals in its new report that an expanding middle class in countries such as India, China, Brazil and Russia is driving growth.
Biomarkers are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, indicate what treatment options may be most effective in an individual patient’s case and predict treatment response. They play a role both in new drug R&D and in predicting the outcome of treatment in the medical setting. They are important tools for understanding disease mechanism, developing more effective treatments and improving the quality of patient care.
The global CNS biomarker market is projected to reach $5.1 billion by 2020 from $3.1 billion in 2015, reflecting a five-year compound annual growth rate (CAGR) of 10.4%. Key market drivers include the increase in public-private partnerships with government support, pressure to keep healthcare costs down, a growing elderly population and the rapid advancement of genomic and proteomic technologies.
The discovery segment of the CNS biomarker market will exhibit modest growth during the next five years, partly because many of the proteins involved in the major CNS disease pathways have been discovered. However, there will likely be new discoveries in the future as proteomics research advances. Projected revenues for CNS biomarker discovery in 2015 is just over $1.9 billion, and this is expected to increase to nearly $3.3 billion by the end of 2020, reflecting a five-year CAGR of 11.7%.
The CNS drug development segment is expected to see the fastest growth, increasing from $303 million in 2015 to $776 million by 2020 with a five-year CAGR of 20.7%. This large increase is due to the number of new compounds entering the clinic from discovery activities in company pipelines.
Before 2015, the CNS molecular diagnostics segment saw tremendous growth. However, as these more validated biomarkers become available for patient segmentation and assessment of efficacy for clinical trials, this market will shift from strictly molecular diagnostics to drug development. Segment revenues should total $901 million and $1 billion in 2015 and 2020, respectively, demonstrating a five-year CAGR of 2.2%. Tests for Alzheimer’s disease, schizophrenia and multiple sclerosis are expected to be key components in the next few years. These disorders represent large markets and have unmet needs in both diagnosis and treatment.
The marketplace continues to globalize. The pharmaceutical and diagnostic industries, which have historically focused on Western markets, have increasingly shifted their focus on emerging markets, chiefly, China, India, Brazil, and Russia.
“In these emerging economies, a growing middle-class is driving market growth. China’s economy saw double-digit growth during the past six to eight years, but has begun slow as it matures,” says BCC Research analyst Jackson Highsmith. “India’s economy is expected to reach double-digit growth in 2016, which may boost the biomarker revenues over the forecast period. Also, India has a strong presence in the market for bioinformatics data, which supports biomarker studies in North America and Europe.”
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets (BIO074C) analyzes the leading and emerging competitors in the biomarkers market. The report profiles manufacturers of leading products, as well as biotechnology companies with novel products in development. Analyses of global market drivers and trends, with data from 2014, 2015, and projections of CAGRs through 2020 also are provided.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at email@example.com.
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets( BIO074C )
Publish Date: Mar 2016
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.